文献速递肝病

综述:原发性胆汁性胆管炎的病理生理与治疗管理

Review article: pathophysiology and management of primary biliary cholangitis.
PubMed 文献 · Aliment Pharmacol Ther · 2020-08-19

本文综述原发性胆汁性胆管炎(PBC)的疾病特征,并回顾以患者为中心的管理方法。PBC诊断通常基于血清肝功能试验和免疫血清学。管理应聚焦三大支柱:生化与预后标准进行风险分层、管理并发症状与相关疾病、分期监测与并发症预防,并鼓励与PBC专家中心讨论。

要点

  • PBC诊断通常基于血清肝功能试验和免疫血清学。
  • 管理三大支柱:风险分层、管理并发症状与相关疾病、分期监测与预防并发症。
  • 鼓励与PBC专家中心讨论管理,包括新获批的奥贝胆酸及替代非获批治疗和临床试验。

核心结论

  • PBC是一种动态疾病,当前治疗目标已适当提高,应优先预防终末期肝病并减轻所有患者的症状负担。

研究设计与样本

  • 本文为综述,回顾当前关于PBC的文献与指南,重点关注管理与治疗。

主要发现

  • PBC为免疫介导性疾病,以肝内胆管破坏为特征,导致胆道进行性损伤、胆汁淤积并最终进展为晚期肝病。
  • PBC的明确诊断通常基于血清肝功能试验和免疫血清学。
  • 管理应聚焦三大过程支柱:通过生化和预后标准进行治疗与风险分层、管理并发症状和其他相关疾病、对疾病分期监测进展并预防并发症。
  • 管理存在持续复杂性,包括新获批的奥贝胆酸、替代非获批治疗及正在进行的临床试验,鼓励与PBC专家中心讨论。

临床怎么用

  • 作者鼓励与PBC专家中心讨论,涉及新获批的奥贝胆酸、替代非获批治疗及正在进行的临床试验。
  • 作者认为管理应聚焦三大过程支柱:风险分层、管理并发症状与相关疾病、分期监测与预防并发症。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Primary biliary cholangitis (PBC), an immune-mediated disease characterised by destruction of intrahepatic bile ducts, results in progressive damage to the biliary tree, cholestasis and ultimately advanced liver disease. In the last decade, advances in practice have improved clinical care, driven novel therapeutic options and improved risk stratification tools. AIMS: To provide an overview of the disease characteristics of PBC and review a patient-centred management approach for the clinical team caring for those with PBC. METHODS: We reviewed the current literature and guidelines on PBC with a focus on management and therapies. RESULTS: A confident diagnosis of PBC is usually made based on serum liver tests and immune serology. Management of PBC should focus on three main 'process' pillars: (a) treat and risk-stratify through use of biochemical and prognostic criteria; (b) manage concurrent symptoms and other associated diseases; and (c) stage disease, monitor progression and prevent complications. With ongoing complexities in management, including a newly licensed therapy (obeticholic acid) and alternative non-licensed treatments and ongoing clinical trials, discussion with PBC expert centres is encouraged. CONCLUSIONS: PBC is a dynamic disease wherein current treatment goals have become appropriately ambitious. Goals of care should prioritise prevention of end-stage liver disease and amelioration of patient symptom burden for all.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Leung KK, Deeb M, Hirschfield GM, et al. Review article: pathophysiology and management of primary biliary cholangitis. Aliment Pharmacol Ther. 2020. PMID: 32813299. doi:10.1111/apt.16023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。